Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H34N2O7 |
| Molecular Weight | 450.5253 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)OC1=CC=C(CC2=C(C)N(N=C2O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C(C)C)C=C1
InChI
InChIKey=GSINGUMRKGRYJP-VZWAGXQNSA-N
InChI=1S/C23H34N2O7/c1-12(2)25-14(5)17(10-15-6-8-16(9-7-15)30-13(3)4)22(24-25)32-23-21(29)20(28)19(27)18(11-26)31-23/h6-9,12-13,18-21,23,26-29H,10-11H2,1-5H3/t18-,19-,20+,21-,23+/m1/s1
Remogliflozin is the active component of the pro-drug remogliflozin etabonate, which is used the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes. Remogliflozin inhibits the sodium-glucose transport proteins (SGLT), is selective for SGLT2, which is responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus. | 2015 |
|
| Remogliflozin etabonate : a novel SGLT2 inhibitor for treatment of diabetes mellitus. | 2015 Aug 14 |
|
| Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice. | 2015 Sep |
Sample Use Guides
Remogliflozin is the active component of the pro-drug remogliflozin etabonate. Using the ORAC assay, it was determined the antioxidant capacity of equal concentrations of remogliflozin etabonate, remogliflozin, canagliflozin and dapagliflozin. It was shown, remogliflozin displayed a robust antioxidant activity compared to the pro-drug and other SGLT2 inhibitors, canagliflozin and dapagliflozin.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
329045-45-6
Created by
admin on Fri Dec 15 21:31:55 GMT 2023 , Edited by admin on Fri Dec 15 21:31:55 GMT 2023
|
PRIMARY | |||
|
DTXSID30186563
Created by
admin on Fri Dec 15 21:31:55 GMT 2023 , Edited by admin on Fri Dec 15 21:31:55 GMT 2023
|
PRIMARY | |||
|
13ZPK7A4MJ
Created by
admin on Fri Dec 15 21:31:55 GMT 2023 , Edited by admin on Fri Dec 15 21:31:55 GMT 2023
|
PRIMARY | |||
|
9846588
Created by
admin on Fri Dec 15 21:31:55 GMT 2023 , Edited by admin on Fri Dec 15 21:31:55 GMT 2023
|
PRIMARY | |||
|
Remogliflozin
Created by
admin on Fri Dec 15 21:31:55 GMT 2023 , Edited by admin on Fri Dec 15 21:31:55 GMT 2023
|
PRIMARY |
PRODRUG (METABOLITE ACTIVE)
SUBSTANCE RECORD
